Blockchain Registration Transaction Record

Regentis Advances GelrinC on Dual Tracks: U.S. Trial Hits 50% Enrollment, European Launch Begins

Regentis Biomaterials (RGNT) advances GelrinC: Phase III trial passes 50% enrollment, European commercialization begins, and manufacturing yield up 400%. Learn more.

This news matters because it signals progress for a novel, off-the-shelf cartilage repair treatment that could offer a faster, less invasive alternative to current cell-based therapies. If the Phase III trial succeeds, GelrinC could become a standard option for knee cartilage defects, potentially improving patient outcomes and reducing healthcare costs. For investors, the parallel advancement in Europe and the U.S. de-risks the timeline, making Regentis a compelling watch in the medtech space.